The use of ranolazine in cardiovascular disease

Bibliography

• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. (2000) 342(3):145–153.
   PubMed Web of Science ®Google Scholar
• SCHOFIELD RS, HILL JA: Role of metabolically active drugs in the management of ischemic heart disease. Am. J. Cardiovasc. Drugs (2001) 1(1):23–35.
   PubMedGoogle Scholar
• •General overview of several drugs under investigation as mediators of myocardial metabolism in chronic heart disease, including ranolazine.
   Google Scholar
• ARSENIAN MA: Carnitine and its derivatives in cardiovascular disease. Frog. Cardiovasc. Dis. (1997) 40(3):265–286.
   PubMed Web of Science ®Google Scholar
• •Excellent review of camitine and its effects in a variety of cardiovascular diseases.
   Google Scholar
• SPAGNOLI LG, CORSI M, VILLASCHI S, PALMIERI G, MACCARI F: Myocardial carnitine deficiency in acute myocardial infarction [letter]. Lancet (1982) 1(8286):1419–1420.
   PubMed Web of Science ®Google Scholar
• ILICETO S, SCRUTINIO D, BRUZZI P et al.: Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J. Am. Coll. Cardiol (1995) 26(2):380–387.
   PubMed Web of Science ®Google Scholar
• BERSIN RM, STACPOOLE PW: Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am. Heart J. (1997) 134(5):841–855.
   PubMed Web of Science ®Google Scholar
• STACPOOLE PW, HARMAN EM, CURRY SH, BAUMGARTNER TG, MISBIN RI: Treatment of lactic acidosis with dichloroacetate. N Engl. J. Med (1983) 309(7):390–396.
   PubMed Web of Science ®Google Scholar
• STACPOOLE PW, WRIGHT EC, BAUMGARTNER TG etal.: A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults: The Dichloroacetate-Lactic Acidosis Study Group. N Eng] J. Med (1992) 327(22):1564–1569.
   Google Scholar
• MOORE GW, SWIFT LL, RABINOWITZ D, CROFFORD OB, OATES JA, STACPOOLE PW: Reduction of serum cholesterol in two patients with homozygous familial hypercholesterolaemia by dichloroacetate. Atherosclerosis (1979) 33(3):285–293.
   PubMed Web of Science ®Google Scholar
• SODI-PALLARES D, TESTELLI M, FISHLEDER F: Effects of an intravenous infusion of a potassium-insulin-glucose solution on the electrocardiographic signs of myocardial infarction. Am. J. Cardiol. (1962) 9:166–181.
   PubMed Web of Science ®Google Scholar
• MALMBERG K, RYDEN L, EFENDIC Set al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J. Am. Coll. Cardiol. (1995) 26(1):57–65.
   Google Scholar
• DIAZ R, PAOLASSO EA, PIEGAS LS et al:Metabolic modulation of acute myocardial infarction: the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation (1998) 98(21):2227–2234.
   PubMed Web of Science ®Google Scholar
• MCCLELLAN KJ, PLOSKER GL: Trimetazidine: a review of its use in stable angina pectoris and other coronary conditions. Drugs (1999) 58(1):143–157.
   PubMed Web of Science ®Google Scholar
• •Excellent overview of trimetazidine, the drug with the most similarities to ranolazine.
   Google Scholar
• DETRY JM, SELLIER P, PENNAFORTE S, COKKINOS D, DARGIE H, MATHES P: Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br. J. CBI]. Pharmacol. (1994) 37(3):279–288.
   Google Scholar
• SZWED H, PACHOCKI R, DOMZAL-BOCHENSKA M et al.: Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina: TRIMPOL I, a multicenter study. Presse Med. (2000) 29(10):533–538.
   PubMed Web of Science ®Google Scholar
• LEVY S, AND THE GROUP OF SOUTH OF FRANCE INVESTIGATORS: Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am. J. Cardiol. (1995) 76(6) Suppl. B:12B–16B.
   Google Scholar
• KILLALEA SM, KRUM H: Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am. J. Cardiovasc. Drugs (2001) 1(3):193–204.
   PubMedGoogle Scholar
• LORENTZ IT, SHORTALL M: Perhexilene neuropathy: a report of two cases. Aust. NZ J. Med. (1983) 13(5):517–518.
   PubMedGoogle Scholar
• HOROWITZ JD, SIA ST, MACDONALD PS, GOBLE AJ, LOUIS WJ: Perhexiline maleate treatment for severe angina pectoris - correlations with pharmacokinetics. Int. J. Cardiol (1986) 13(2):219–229.
   PubMed Web of Science ®Google Scholar
• HUTTER JF, PIPER HM, SPIECKERMANN PG: Effects of fatty acid oxidation on efficiency of energy production in rat hearts. Am. J. Physiol (1985) 249:H723–H729.
   Web of Science ®Google Scholar
• MCCORMACK JG, STANLEY WC, WOLFF AA: Ranolazine: a novel metabolic modulator for the treatment of angina. am Pharmac. (1998) 30(5):639–645.
   Google Scholar
• ••Excellent review of the predinical andclinical data on ranolazine, particularly regarding the mechanism of action of the drug.
   Google Scholar
• ALLELY MC, ALPS BJ: Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br Pharmacol. (1990) 99(1):5–6.
   PubMed Web of Science ®Google Scholar
• ALLELY MC, BROWN CM, KENNY BA, KILPATRICK AT, MARTIN A, SPEDDING M: Modulation of alpha-adrenoceptors in the rat left ventricle by ischemia and acyl carnitines: protection by ranolazine. j Cardiovasc. Pharmac. (1993) 21(6):869–873.
   PubMed Web of Science ®Google Scholar
• GRALINSKI MR, BLACK SC, KILGORE KS, CHOU AY, MCCORMACK JG, LUCCHESI BR: Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc. Res. (1994) 28(8):1231–1237.
   PubMed Web of Science ®Google Scholar
• MCCORMACK JG, BARR RL, WOLFF AA, LOPASCHUK GD: Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation (1996) 93(1):135–142.
   PubMed Web of Science ®Google Scholar
• CLARK B, WYATT KM, MCCORMACK JG: Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J. Mal Cell Cardiol. (1996) 28(2):341–350.
   PubMed Web of Science ®Google Scholar
• PENMAN AD, EADIE J, HERRON WJ, REILLY MA, RUSH WR, LIU Y: The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. Rapid Commun. Mass Spectrom. (1995) 9(14):1418–1430.
   PubMed Web of Science ®Google Scholar
• JAIN D, DASGUPTA P, HUGHES LO, LAHIRI A, RAFTERY EB: Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur. Pharmacol (1990) 38(2):111–114.
   Web of Science ®Google Scholar
• THADANI U, EZEKOWITZ M, FENNEY L, CHIANG YK: Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris: Ranolazine Study Group. Circulation (1994) 90(2):726–734.
   PubMed Web of Science ®Google Scholar
• COCCO G, ROUSSEAU MF, BOUVY T et al.: Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. j Cardiovasc. Pharmacol (1992) 20(1):131–138.
   PubMed Web of Science ®Google Scholar
• PEPINE CJ, WOLFF AA: A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am. J. Cardiol. (1999) 84(1):46–50.
   PubMed Web of Science ®Google Scholar
• ROUSSEAU MF, VISSER FG, BAX JJ et al: Ranolazine: antianginal therapy with a novel mechanism: placebo controlled comparison versus atenolol. Eur. Heart 1. (1994) 15(Suppl.):95.
   Google Scholar
• WOLFF AA: MARISA: Monotherapy Assessment of Ranolazine in Stable Angina (MARISA). J. Am. Coll. Cardiol. (2000) 35(2) Suppl. A:408A.
   Google Scholar
• ••Pivotal randomised, double-blind, placebo-controlled crossover study which demonstrated the benefit of a sustained-release preparation of ranolazine.
   Google Scholar
• JANSKY P, SKETTON S, CHAITMAN BR eta].: Comparative antianginal efficacy of randolazine in young (65 years) versus elderly (.65 years) patients: results of the MARISA trial. Circulation (2000) 102(18) Suppl. II:II–712.
   Google Scholar
• CHAITMAN BR, SKETTINO S, DEQUATTRO V et al.: Improved exercise performance on ranolazine in patients with chronic angina and a history of heart failure: the MARISA Trial. J. Am. Coll. Cardiol (2001) 37(2, Suppl. A):149A.
   Google Scholar
• DEQUATTRO V, SKETTINO S, CHAITMAN BR et al: Comparative antianginal efficacy and tolerability of ranolazine in diabetic and nondiabetic patients: Results of the MARISA trial. j Am. Coll. Cardiol (2001) 37(2, Suppl. A):338A.
   Google Scholar
• THE CARISA TRIAL INVESTIGATORS: The Combination Assessment of Ranolazine In Stable Angina (CARISA) trial. Late breaking clinical trial session. American Heart Association Annual Scientific Session. Anaheim, California, USA. (14th November, 2001).
   Google Scholar
• ••Large multi-national trial in over 800patients, demonstrating the benefit of ranolazine in combination with standard antianginal therapy.
   Google Scholar
• SABBAH HN, MISHIMAT, BIESIADECKI BJ et al.: Ranolazine improves left ventricular performance in dogs with chronic heart failure. j Am. Coll. Cardiol. (2000) 35(2) Suppl. A:218A.
   Google Scholar
• SABBAH HN, CHANDLER IVP, SUZUKI G et al.: Ranolazine improves left ventricular mechanical efficiency in dogs with heart failure: comparison with dobutamine. j Am. Coll. Cardiol (2001) 37(2) Suppl. A:173A.
   Google Scholar